EGFR and non-small cell lung carcinoma: Currently, combination therapy is playing a leading role in drug resistance, for example ABT-199 has had a synergistic effect on positive NSCLC for EGFR mutations resistant to anti-EGFR inhibitors (tyrosine kinase inhibitor) [22, 23], based on these studies, our research team proposed that ABT-199 could also exhibit a synergistic effect in combination with ALKi, our results evidence that there was synergistic effect in WT and G1202R mutant cell models, while C1156Y and L1196M exhibited good combination with crizotinib, ceritinib and alectinib.